Head to Head Contrast: Inhibikase Therapeutics (NYSE:IKT) Versus Applied Genetic Technologies (NASDAQ:AGTC)
Head to Head Contrast: Inhibikase Therapeutics (NYSE:IKT) Versus Applied Genetic Technologies (NASDAQ:AGTC)
Inhibikase Therapeutics (NYSE:IKT – Get Rating) and Applied Genetic Technologies (NASDAQ:AGTC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.
Inhibikase Treateutics(紐約證券交易所代碼：IKT-GET Rating)和應用基因技術公司(納斯達克：AGTC-GET Rating)都是小盤醫療公司，但哪一家更好？我們將根據這兩家公司的估值、股息、分析師建議、風險、機構所有權、盈利能力和收益的強弱對其進行對比。
Profitability
盈利能力
This table compares Inhibikase Therapeutics and Applied Genetic Technologies' net margins, return on equity and return on assets.
此表比較了Inhibikase治療公司和應用基因技術公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Inhibikase Therapeutics | -4,894.27% | -51.81% | -46.77% |
| Applied Genetic Technologies | N/A | -98.79% | -60.15% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 抑制酶療法 | -4,894.27% | -51.81% | -46.77% |
| 應用基因技術 | 不適用 | -98.79% | -60.15% |
Institutional and Insider Ownership
機構和內部人持股
13.3% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 22.1% of Applied Genetic Technologies shares are held by institutional investors. 24.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 4.1% of Applied Genetic Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Inhibikase治療公司13.3%的股份由機構投資者持有。相比之下，應用基因技術公司22.1%的股份由機構投資者持有。Inhibikase治療公司24.3%的股份由內部人士持有。相比之下，應用基因技術公司4.1%的股份由內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一家公司有望實現長期增長。
Earnings & Valuation
收益與估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibikase Therapeutics | $3.10 million | 7.32 | -$14.79 million | ($0.74) | -1.22 |
| Applied Genetic Technologies | $500,000.00 | 29.42 | -$57.83 million | ($1.46) | -0.20 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 抑制酶療法 | 310萬美元 | 7.32 | -1,479萬元 | ($0.74) | -1.22 |
| 應用基因技術 | $500,000.00 | 29.42 | -5783萬美元 | ($1.46) | -0.20 |
Inhibikase Therapeutics has higher revenue and earnings than Applied Genetic Technologies. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.
Inhibikase治療公司的收入和收益比應用基因技術公司高。Inhibikase治療公司的市盈率低於應用基因技術公司，這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings for Inhibikase Therapeutics and Applied Genetic Technologies, as provided by MarketBeat.com.
這是MarketBeat.com提供的Inhibikase治療技術和應用基因技術最近的評級細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibikase Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Applied Genetic Technologies | 0 | 1 | 4 | 0 | 2.80 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 抑制酶療法 | 0 | 0 | 0 | 0 | 不適用 |
| 應用基因技術 | 0 | 1 | 4 | 0 | 2.80 |
Applied Genetic Technologies has a consensus target price of $6.50, indicating a potential upside of 2,141.38%. Given Applied Genetic Technologies' higher possible upside, analysts clearly believe Applied Genetic Technologies is more favorable than Inhibikase Therapeutics.
應用基因技術公司的共識目標價為6.50美元，表明潛在漲幅為2,141.38%。考慮到應用基因技術的更高可能的上行空間，分析人士顯然認為應用基因技術比Inhibikase治療更有利。
Volatility and Risk
波動性和風險
Inhibikase Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Inhibikase Treateutics的貝塔係數為1.19，這意味着其股價的波動性比標準普爾500指數高19%。相比之下，應用基因技術公司的貝塔係數為1.26，這意味着其股價的波動性比標準普爾500指數高26%。
Summary
摘要
Applied Genetic Technologies beats Inhibikase Therapeutics on 7 of the 13 factors compared between the two stocks.
應用基因技術公司在兩隻股票之間的13個因素中有7個超過了Inhibikase治療公司。
About Inhibikase Therapeutics
關於Inhibikase療法
(Get Rating)
(獲取評級)
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
臨牀階段製藥公司Inhibikase Treateutics，Inhibikase Treeutics，Inhibikase Treateutics，Inhibikase Treateutics，Inc.是一家臨牀階段製藥公司，開發帕金森氏病(PD)和大腦內外相關疾病的療法。該公司的候選產品包括用於治療帕金森氏症以及帕金森氏症早期症狀(如吞嚥、吞嚥困難、神經原性便祕和多系統萎縮)的小分子阿貝爾森酪氨酸激酶抑制劑IKT-148009；以及抗癌藥物伊馬替尼的前藥IKT-001Pro，該藥物正處於臨牀前開發階段，旨在將胃腸道副作用降至最低，並用於治療血液和胃癌。它還參與開發其他神經疾病的各種研究計劃。該公司與約翰·霍普金斯大學、亞利桑那州立大學、密歇根州立大學以及路易斯安那州立大學有研發合作。Inhibikase治療公司成立於2008年，總部設在佐治亞州亞特蘭大。
About Applied Genetic Technologies
關於應用基因技術
(Get Rating)
(獲取評級)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.
應用基因技術公司是一家臨牀階段的生物技術公司，為患有罕見和衰弱疾病的患者開發變革性基因療法。其先進的候選產品包括兩個目標的三個眼科開發計劃，包括正在進行I/II階段臨牀試驗的X連鎖視網膜色素變性；以及正在進行I/II階段臨牀試驗的色盲。該公司還在開發一種候選光遺傳產品，用於治療晚期視網膜疾病。此外，該公司還啟動了一個耳科臨牀前項目；以及兩個針對中樞神經系統疾病的臨牀前項目，包括額顳痴呆和肌萎縮側索硬化症。它與佛羅裏達大學、仿生視覺有限責任公司和Otmey公司簽訂了合作協議。應用基因技術公司成立於1999年，總部設在佛羅裏達州阿拉丘亞市。
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Inhibikase治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Inhibikase Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。